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tion (PCI) ischemic events, in a small sample size, single-center
study (2) with good negative predictive value but poor specificity.
Is it too early? Indeed, before adapting clopidogrel loading dose,
maybe we should define a consensual definition of nonresponse?
The difference observed between both groups is highly signifi-
cant, with no clinical events in the VASP-guided group. This
result could suggest that all post-PCI ischemic events are related to
nonresponse to clopidogrel, which is probably excessive. These
recurrences involve a complex and multifactorial process. The
recent TRITON–TIMI 38 (Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet Inhibition with
Prasugrel–Thrombolysis In Myocardial Infarction) study showed
that, even with a more potent P2Y12 inhibitor, the rate of
recurrent events significantly decreased but continued to exist (4).
The authors reported no excess of major bleeding in the
VASP-guided group and concluded that the strategy is safe.
However, the sample size of the present study does not allow for
such a definite conclusion. What would be the bleeding compli-
cations in a broad population of such strategy? Moreover, in the
whole population, 52% of the patients had VASP 50%, suggest-
ing the use of this strategy in more than one-half of the PCI
patients. Then, will the increased length in hospital stay be
acceptable for the public health system?
Is it too late? Indeed, in the near future, the alternative in
nonresponders might be to switch to alternative drugs such as
prasugrel. Then, the variability of response to clopidogrel would
become a resolved issue.
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Reply
We thank Dr. Cuisset and colleagues for their critical review of our
study (1). Many studies have suggested a stepwise relationship
between platelet reactivity (PR) and ischemic recurrences after
percutaneous coronary intervention (PCI), and the vasodilator-
stimulated phosphoprotein index has been used extensively used in
these trials. The threshold used to define low response in the
present study was chosen according to its clinical and biological
relevance (2–5). Further, this cut-off value exhibits a very high
negative predictive value and a low positive predictive value, which
illustrate the fact that, although ischemic recurrences are multifac-
torial, PR plays a key role.
Dr. Cuisset and colleagues seem to misunderstand available data
on PR and the hypothesis tested in our study. The interindividual
variability observed between patients in response to clopidogrel
means that the effect of a 2,400-mg loading dose for low
responders is inferior to that of 600 mg for good responders!
Indeed, available data support the fact that the response to the
drug, and not the dose, determines the outcome.
Finally, Dr. Cuisset and colleagues question the relevance of the
present study with regard to the future marketing of prasugrel. The
present trial is a landmark study demonstrating that PR is a
modifiable risk factor for recurrent ischemic events and therefore of
major interest not only for clopidogrel but for all other antiplatelet
therapies that will be developed. Further, consistent with our
results, researchers from the TRITON–TIMI 38 (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing Platelet
Inhibition with Prasugrel–Thrombolysis In Myocardial Infarction)
study observed that greater PR inhibition, as achieved by prasugrel,
compared with standard clopidogrel therapy, resulted in lower
rates of ischemic events in patients undergoing PCI for acute
coronary syndromes (6). However, achieving 90% PR inhibition
with prasugrel resulted in a significant increase in major bleedings.
Accordingly, the authors do not support the use of prasugrel for
large subgroups of patients, including the elderly, those patients of
low weight, those patients with previous stroke, and those patients
undergoing elective PCI, which make up more than half of our
patients. In addition, finding a threshold of PR to decrease
ischemic events could be of great interest for the new P2Y12
ADP-receptor inhibitors to increase their risk/benefit ratio. Until
prasugrel is available, platelet monitoring of the response to
clopidogrel carries a potential clinical benefit for patients under-
going PCI. We believe that it is never too late to improve both our
practice and patient outcomes.
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Pulmonary Artery Hypertension:
The Link Between Prostanoids
and Bloodstream Infections
Because of their vasodilatory and antiproliferative effects, the
administration of prostanoids has become an important part of
treatment for patients with pulmonary arterial hypertension
(PAH). The intravenous infusion of the 2 prostanoids, epoproste-
nol (epoprostenol sodium [brand name Flolan, Glaxo SmithKline,
Research Triangle Park, North Carolina]) and treprostinil (trepro-
stinil sodium [brand name Remodulin, United Therapeutics,
Silver Spring, Maryland]) are approved by the U.S. Food and Drug
Administration for use in patients with PAH and are commonly
used in many centers today. These drugs are discussed by Chin and
Rubin (1) in their review on the topic in a recent issue of the
Journal. However, there is no mention of the caution raised by a
study performed at 7 PAH centers during 2003 to 2006 by the
Centers for Disease Control and Prevention (CDC) on the
possible link between treprostinil and greater rates of bloodstream
infections (BSIs); (primarily gram-negative infections) when com-
pared with the use of intravenous epoprostenol (2). The overall
BSI pooled mean rate (per 1,000 medicine days) was 1.11 for
patients receiving treprostinil compared with 0.43 in those receiv-
ing epoprostenol (pooled incidence rate ratio: 2.57; 95% confi-
dence interval: 1.81 to 3.64). The pooled mean rate for gram-
negative BSIs was 0.76 among patients on treprostinil compared
with 0.06 in patients on epoprostenol (pooled incidence rate ratio:
12.77; 95% confidence interval: 6.55 to 26.80) (2). The CDC
noted that “health-care providers who care for PAH patients
should be aware of these findings.” The reasons for these observed
differences are unknown and may in part be related to the drug’s
differing anti-inflammatory effects. Therefore, further studies are
needed to determine the reason for the observed increased BSI rate
with treprostinil when compared with epoprostenol.
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(1). Bloodstream infections are an important complication of indwell-
ing catheters and, in this Centers for Disease Control and Prevention
(CDC) report, the overall infection rate with treprostinil was signif-
icantly greater than that of epoprostenol (incidence rate ratio 2.57,
95% confidence interval: 1.81 to 3.64). The rate of gram-negative
infections was also much greater with treprostinil, with gram-
negative infections actually more common than gram-positive
infections. This finding suggests that, when line infection is
suspected in patients receiving intravenous treprostinil, the empiric
use of antibiotics with both gram-positive and -negative coverage
should be considered until blood culture results are available.
However, these findings do not rise to the level of robust
scientific proof: First, just before the initiation of the study, an alert
letter from United Therapeutics (Silver Spring, Maryland), the
manufacturer of treprostinil, was distributed requesting that phy-
sicians report any gram-negative bacteremia cases for further
evaluation. Shortly after this concern was raised, the CDC asked
centers where treprostinil was used frequently to participate in a
more formal study. It is possible that centers with increased rates
of gram-negative infections were more likely to participate, par-
ticularly given the increased awareness prompted by the alert letter.
Second, there appeared to be significant heterogeneity within the
results, with incidence rate ratios for infections with treprostinil
compared with epoprostenol ranging from 0.59 to 3.90 across the
5 centers from which data were available for both medications.
Finally, data were collected retrospectively and over different years
at each site, the CDC was not directly involved in the data
collection at most sites, and the information was only presented as
a 2-page brief rather than a full, peer-reviewed research paper.
Thus, although the CDC report raises awareness to the risk and
provides guidance for the current treatment of suspected line
infections, additional formal study is required.
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